Phase 2b data show iopofosine I-131 drives deep, durable responses in relapsed Waldenström macroglobulinemia after BTK inhibitors, with manageable cytopenias.
Related to this article
FDA accepts updated tab-cel BLA for EBV+ PTLD after transplant, adding ALLELE data; PDUFA decision set for March 31, 2027.
Real-world German MINT data show mogamulizumab delivers durable responses, ~20-month PFS, manageable safety, and improved quality of life in MF and Sézary syndrome.
Theodore Wagener, PhD, of The Ohio State University discusses the design of the phase 2 DREAM LUNG study of psilocybin-assisted therapy for depression in non–small cell lung cancer.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
VS-7375 Shows Antitumor Activity in PDAC, Other KRAS G12D–Mutant Tumors
2
Invikafusp Alfa Receives Second FDA Fast Track Designation for TMB-High Solid Tumors
3
Iopofosine I 131 Shows Activity in Post-BTKi Waldenström Macroglobulinemia
4
Dr Simmons on Payer Barriers and Safety in Community-Based CAR T-Cell Therapy
5